DOCSLIB.ORG

Combination Therapy of Angiotensin Receptor Blocker with Statin Or Thiazolidinediones As Promising Therapeutic Strategy for Metabolic Syndrome and Atherosclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination Therapy of Angiotensin Receptor Blocker with Statin Or Thiazolidinediones As Promising Therapeutic Strategy for Metabolic Syndrome and Atherosclerosis Hypertension Research (2009) 32, 639–640 & 2009 The Japanese Society of Hypertension All rights reserved 0916-9636/09 $32.00 www.nature.com/hr COMMENTARY Combination therapy of angiotensin receptor blocker with statin or thiazolidinediones as promising therapeutic strategy for metabolic syndrome and atherosclerosis Shokei Kim-Mitsuyama Hypertension Research (2009) 32, 639–640; doi:10.1038/hr.2009.90; published online 19 June 2009 ypertension, insulin resistance/type 2 have multiple protective effects against remodeling in DS rats are at least partially H diabetes and hypercholesterolemia are vascular endothelial dysfunction and athero- attributed to a greater attenuation of tissue closely associated with each other, and they sclerosis, being mediated by anti-inflammatory oxidative stress and inflammation, indepen- all cause vascular endothelial dysfunction, and antioxidative effects.1,7 Interestingly, in dent of blood pressure and plasma cholesterol develop atherosclerosis and consequently both preclinical and clinical studies, the com- control. Furthermore, the additive improve- increase cardiovascular morbidity and mor- bination of an RAS blocker and a statin is ment of the vascular endothelial function by tality.1 Very importantly, there is a strong reported to provide additive beneficial effects the combination is mediated by both the synergy among hypertension, type 2 diabetes, on vascular endothelial dysfunction, athero- inhibition of endothelial nitric oxide synthase and hypercholesterolemia in terms of the risk sclerosis, inflammation or oxidative stress. uncoupling by olmesartan and the enhance- factors for the development of cardiovascular In this issue of Hypertension Research, ment of Akt phosphorylation by pravastatin. diseases. The frequent association of these Kanno et al.,8 have extended the benefits of Our previous study10 provides the mechan- diseases aggravates the process of vascular combination therapy of a statin and an ARB. isms underlying earlier clinical findings11 that endothelial dysfunction and atherosclerosis They have shown that the combination of the combination of a statin (simvastatin) with in patients with these comorbid conditions. pravastatin and olmesartan provided a syner- an ARB (losartan) improves endothelial func- Renin–angiotensin system (RAS) blockers, gistic improvement of glucose tolerance in tion and reduces inflammatory markers to a such as angiotensin-converting enzyme inhi- type 2 diabetic mice, and this synergistic greater extent than does either monotherapy bitors and AT1 receptor blockers (ARBs), are effect was associated with the enhancement in hypercholesterolemic, hypertensive patients. shown to be effective for the treatment of not of glucose uptake in skeletal muscle and Taken together with the report by Kanno only hypertension but also cardiovascular and adipose tissue. They have also demonstrated et al.,8 the combination of a statin and an renal diseases, by exerting multiple pleiotro- that the attenuation of tissue oxidative stress ARB is predicted to provide additive benefits pic effects, including the suppression of by combination therapy is involved in the in the prevention of cardiovascular diseases, cardiovascular hypertrophy and remodeling, synergistic improvement of insulin sensitivity through differential pleiotropic effects. the improvement of insulin sensitivity due to the combination. Furthermore, the More than half of hypertensive patients and vascular endothelial function, and anti- same group of investigators has previously are associated with insulin resistance and/or inflammatory and antioxidative effects.2–4 reported that a statin (fluvastatin) enhances type 2 diabetes, and the coexistence of hyper- Furthermore, RAS blockers are reported the inhibitory effects of an ARB (valsartan) tension and diabetes markedly increases to reduce the incidence of new-onset on atherosclerotic changes in apolipoprotein cardiovascular morbidity and mortality.12 diabetes in high-risk or hypertensive E-deficient mice.9 Taken together, Kanno Therefore, the development of an appropriate patients.5 3-hydroxy-3-methylglutaryl coen- et al.,8 propose that the combination of a therapeutic strategy for hypertensive patients zyme A (HMG CoA) reductase inhibitors statin and an ARB could confer a promising with diabetes is a key issue in achieving a (statins) are the most popular drugs for therapeutic strategy for metabolic syndrome successful reduction of cardiovascular dis- treatment of hypercholesterolemia and are and atherosclerosis. eases. Thiazolidinediones (TZDs),13 such as shown to reduce cardiovascular morbidity Previously, we have also reported that the pioglitazone, are synthetic peroxisome prolif- and mortality in high-risk patients.1,6 Similar combination of an ARB (olmesartan) and a erator-activated receptor-g agonists that act to RAS blockers, statins are well-known to statin (pravastatin) offers more beneficial as an insulin sensitizer and are widely used as effects on cardiovascular hypertrophy and one of the major therapeutic drugs for type 2 remodeling, and vascular endothelial dys- diabetes. Interestingly, clinical evidence14 Professor S Kim-Mitsuyama is at the Department of function in salt-loaded Dahl salt-sensitive indicates that pioglitazone not only Pharmacology and Molecular Therapeutics, Kumamoto hypertensive rats (DS rats) than does either ameliorates hyperglycemia by improving University Graduate School of Medical Sciences, 1-1-1 10 Honjyo, Kumamoto 860-8556, Japan. monotherapy. Greater protective effects of insulin sensitivity but also reduces the E-mail: [email protected] their combination against cardiovascular incidence of cardiovascular events in high- Commentary 640 3 Prasad A, Quyyumi AA. Renin-angiotensin system Statins ARBs TZDs and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507–1512. 4 Yamamoto E, Dong YF, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Olmesartan prevents cardio- vascular injury and hepatic steatosis in obesity Beneficial pleiotropic effects and diabetes, accompanied by apoptosis signal regulat- ing kinase-1 inhibition. Hypertension 2008; 52: 573–580. Anti-oxidative stress 5 Abuissa H, Jones PG, Marso SP, O’Keefe Jr JH. Angio- Anti-inflammation tensin-converting enzyme inhibitors or angiotensin Improvement of endothelial function receptor blockers for prevention of type 2 diabetes: a Anti-atherosclerosis meta-analysis of randomized clinical trials. JAmColl Cardiol 2005; 46: 821–826. 6 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. NEnglJMed1995; 333: 1301–1307. 7 Koh KK, Han SH, Quon MJ. Inflammatory markers Additive or synergistic organ protection and the metabolic syndrome: insights from thera- peutic interventions. J Am Coll Cardiol 2005; 46: Figure 1 Beneficial pleiotropic effects of statins, angiotensin receptor blockers (ARBs) and 1978–1985. 8 Kanno H, Iwai M, Inaba S, Senba I, Nakaoka H, Sone thiazolidinediones (TZDs). These different classes of drugs, by different mechanisms, attenuate tissue H, Mogi M, Horiuchi M. Improvement of glucose intol- oxidative stress and inflammation, leading to the amelioration of vascular endothelial dysfunction, erance by combination of pravastatin and olmesartan in atherosclerosis and cardiovascular remodeling. type 2 diabetic KK-Ay mice. Hypertens Res 2009; 32: 706–711. 9 Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. risk type 2 diabetic patients, beyond blood From the preclinical studies described above, Fluvastatin enhances the inhibitory effects of a selec- tive angiotensin II type 1 receptor blocker, valsartan, on glucose control. Importantly, emerging there is a strong scientific rationale for com- vascular neointimal formation. Circulation 2003; 107: evidence shows that pioglitazone exerts mul- bining an ARB with a statin or a 106–112. tiple beneficial pleiotropic effects on not only TZD in terms of treatment of cardiovascular 10 Yamamoto E, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Lai ZF, Dong YF, Matsuba S, Ogawa H, adipose tissue but also cardiovascular and diseases in high-risk comorbid patients Kim-Mitsuyama S. Pravastatin enhances beneficial 13,15 cerebral tissues. As the mechanisms (Figure 1). The combination of these different effects of olmesartan on vascular injury of salt-sensitive underlying pleiotropic effects differ between classes of drugs, besides normalization of hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 2007; 27:556–563. pioglitazone and the RAS blocker, the com- blood pressure, lipid metabolism or blood 11 Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, bination of these different classes of agents is glucose, exerts an additive or synergistic sup- Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. expected to exert an additive benefit in the pression of vascular endothelial dysfunction Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, reduction of cardiovascular morbidity and and atherosclerosis through a potent attenua- hypertensive patients. Circulation 2004; 110: mortality. We have previously examined the tion of oxidative stress and inflammation. 3687–3692. potential benefit of a combination of an Hence, a combination of an ARB with a statin 12 Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobi- gio R, Filippucci L,
Load more

Recommended publications
  • What Precautions Should We Use with Statins for Women of Childbearing
    CLINICAL INQUIRIES What precautions should we use with statins for women of childbearing age? Chaitany Patel, MD, Lisa Edgerton, PharmD New Hanover Regional Medical Center, Wilmington, North Carolina Donna Flake, MSLS, MSAS Coastal Area Health Education Center, Wilmington, NC EVIDENCE- BASED ANSWER Statins are contraindicated for women who are on its low tissue-penetration properties. pregnant or breastfeeding. Data evaluating statin Cholesterol-lowering with simvastatin 40 mg/d did use for women of childbearing age is limited; how- not disrupt menstrual cycles or effect luteal phase ever, they may be used cautiously with adequate duration (strength of recommendation: C). contraception. Pravastatin may be preferred based CLINICAL COMMENTARY Use statins only as a last resort Before reading this review, I had not been for women of childbearing age ® Dowdenaware Health of the serious Media effects of statin medications I try to follow the USPSTF recommendations and on the developing fetus. In conversations with not screen women aged <45 years without coro- my colleagues, I found that the adverse effects nary artery disease riskCopyright factors for Fhyperlipidemia.or personalof usestatins onlyduring pregnancy are not readily When a woman of any age needs treatment, my known. Such information needs to be more first-line therapy is lifestyle modification. Given the widely disseminated. risks of statin drugs to the developing fetus, Ariel Smits, MD women with childbearing potential should give Department of Family Medicine, Oregon Health & Science fully informed consent and be offered reliable University, Portland contraception before stating statin therapy. I Evidence summary anal, cardiac, tracheal, esophageal, renal, Hydroxymethyl glutaryl coenzyme A and limb deficiency (VACTERL associa- (HMG CoA) reductase inhibitors, com- tion), intrauterine growth retardation monly called statins, have been on the (IUGR), and demise in fetuses exposed market since the late 1980s.
    [Show full text]
  • Effect of Statins and ACE Inhibitors Alone and in Combination on Clinical Outcome in Patients with Coronary Heart Disease
    Journal of Human Hypertension (2004) 18, 781–788 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease VG Athyros1, DP Mikhailidis3, AA Papageorgiou2, VI Bouloukos1, AN Pehlivanidis1, AN Symeonidis4 and M Elisaf5, for the GREACE Study Collaborative Group 1Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 2Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London, UK; 32nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 4Greek Society of General Practitioners, Thessaloniki, Greece; 5Department of Internal Medicine, Medical School, University of Ioannina, Greece We assessed the ‘synergy’ of statins and angiotensin- point in group A was 31%, (95% CI À48 to À6%, P ¼ 0.01) converting enzyme inhibitors (ACEI) in reducing vascu- in comparison to group B, 59% (95% CI À72 to À48%, lar events in patients with coronary heart disease (CHD). Po0.0001) to group C and 63% (95% CI À74 to À51%, The GREek Atorvastatin and CHD Evaluation (GREACE) Po0.0001) to group D. There was no significant Study, suggested that aggressive reduction of low difference in RRR between groups C and D (9%, CI density lipoprotein cholesterol to 2.59 mmol/l À27–10%, P ¼ 0.1). Other factors (eg the blood pressure) (o100 mg/dl) significantly reduces morbidity and mor- that can influence clinical outcome did not differ tality in CHD patients, in comparison to undertreated significantly between the four treatment groups.
    [Show full text]
  • Get the Facts: What You Need to Know About Statins
    Get the Facts: What You Need to Know About Statins We hear a lot about lowering our cholesterol by eating a low-fat diet and getting regular exercise. But for some people, making healthy changes isn’t enough. That’s when statins come in. Statins are medicines that reduce the risk of heart disease and stroke, two of the leading causes of death in the United States. These medicines keep the liver from making cholesterol and help it get rid of cholesterol in the blood. Statins may help if you have high cholesterol, heart disease or are at high risk for heart disease or stroke. Things that can put you at high risk include being a current or former smoker, stress, having diabetes and/or high blood pressure, having a family history of heart disease or stroke, or being overweight. This means you do not have to have high cholesterol to benefit from taking statins. What Are Some Examples of Statins? Below is a list of statins you may have heard of and where you can find them on the SCAN Health Plan® Formulary (Note: The SCAN Formulary and the Formulary tier are subject to change, especially from year to year.): Statin Formulary Status Brand Name Generic Name Lipitor® Atorvastatin Tier 1 Mevacor® Lovastatin Tier 1 Pravachol® Pravastatin Tier 1 Zocor® Simvastatin Tier 1 Crestor® Rosuvastatin Tier 2 Lescol® Fluvastatin Not available Livalo® Pitavastatin Not available Statins can also be combined with other cholesterol-lowering and blood pressure drugs into one pill but may have higher copays. If you have questions about these combination pills and their copays, please talk to your pharmacist.
    [Show full text]
  • FDA Requests Removal of Strongest Warning Against Using Cholesterol
    FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins Breastfeeding not recommended in patients who require statins 7-20-2021 FDA Drug Safety Communication What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant patients. Despite the change, most patients should stop statins once they learn they are pregnant. We have conducted a comprehensive review of all available data and are requesting that statin manufacturers make this change to the prescribing information as part of FDA’s ongoing effort to update the pregnancy and breastfeeding information for all prescription medicines. Patients should not breastfeed when taking a statin because the medicine may pass into breast milk and pose a risk to the baby. Many can stop statins temporarily until breastfeeding ends. However, patients requiring ongoing statin treatment should not breastfeed and instead use infant formula or other alternatives. What is FDA doing? We are requesting revisions to the information about use in pregnancy in the prescribing information of the entire class of statin medicines. These changes include removing the contraindication against using these medicines in all pregnant patients. A contraindication is FDA’s strongest warning and is only added when a medicine should not be used because the risk clearly outweighs any possible benefit. Because the benefits of statins may include prevention of serious or potentially fatal events in a small group of very high-risk pregnant patients, contraindicating these drugs in all pregnant women is not appropriate.
    [Show full text]
  • Analgesic Drug Use Associated with Statin Prescription – a Cross- Sectional Study in Primary Care Settings D
    16 Current Drug Safety, 2012, 7, 16-20 Analgesic Drug Use Associated with Statin Prescription – A Cross- Sectional Study in Primary Care Settings D. Moßhammer*,1, J. Schwarz1, S. Meznaric1, R. Muche2, G. Lorenz1 and K. Mörike3 1Division of General Practice, University Hospital Tübingen, Germany 2Institute of Biometrics, University of Ulm, Germany 3University Hospital Tübingen, Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, Germany Abstract: Background: To investigate whether features of muscular complaints (MC) differ between receivers of a statin prescription and non-receivers. To analyze the relationship between analgesics prescription, statin prescription and/or musculoskeletal disorders. Methods: Cross-sectional study. Consecutive patients in offices of family practitioners were interviewed using a standardized questionnaire. Target variables: Rates of features of MC in patients with or without a statin prescription and rates of analgesic drug prescription in patients with or without statin prescription and/or musculoskeletal disorders. Odds ratios (adjusted for age, sex, and socio-economic status) were calculated using logistic regression analysis. Results: 1135 patients in 26 general practitioners’ offices were asked to participate, and 1031 patients agreed. Features of MC did not differ between the two groups of patients. Analgesic prescription was found to be associated with statin prescription in patients without musculoskeletal disorders (OR 2.2, CI 1.1-4.7 without statin, OR 2.5, CI 0.9-6.9 with statin) and particularly in those with musculoskeletal disorders (OR 5.2, CI 2.9-9.3 without statin, OR 9.3, CI 4.5-19.1 with statin). Conclusions: Analgesic prescriptions are probably positively associated with statin prescription.
    [Show full text]
  • Effects of Statins on Renin–Angiotensin System
    Journal of Cardiovascular Development and Disease Review Effects of Statins on Renin–Angiotensin System Nasim Kiaie 1,†, Armita Mahdavi Gorabi 1,†, Željko Reiner 2, Tannaz Jamialahmadi 3,4, Massimiliano Ruscica 5 and Amirhossein Sahebkar 6,7,8,9,* 1 Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran; [email protected] (N.K.); [email protected] (A.M.G.) 2 Department of Internal Diseases, School of Medicine, University Hospital Center Zagreb, Zagreb University, 10000 Zagreb, Croatia; [email protected] 3 Quchan Branch, Department of Food Science and Technology, Islamic Azad University, Quchan 9479176135, Iran; [email protected] 4 Department of Nutrition, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 5 Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy; [email protected] 6 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 7 Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran 8 School of Medicine, The University of Western Australia, Perth 6009, Australia 9 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran * Correspondence: [email protected] or [email protected] † Equally contributed. Abstract: Statins, a class of drugs for lowering serum LDL-cholesterol, have attracted attention because of their wide range of pleiotropic effects. An important but often neglected effect of statins is their role in the renin–angiotensin system (RAS) pathway. This pathway plays an integral role in the progression of several diseases including hypertension, heart failure, and renal disease.
    [Show full text]
  • Behavioral and Pharmacoepidemiological Risk Factors and Mediators for Type Ii Diabetes Mellitus
    BEHAVIORAL AND PHARMACOEPIDEMIOLOGICAL RISK FACTORS AND MEDIATORS FOR TYPE II DIABETES MELLITUS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Victoria A. Zigmont, BS, MPH Graduate Program in Public Health The Ohio State University 2015 Dissertation Committee: Susan Olivo-Marston, PhD, MPH, Advisor Stephen Clinton, MD, PhD Randall Harris, MD, PhD Gail Kaye, PhD, RD, LD, PLCC Abigail Shoben, PhD Copyright by Victoria A. Zigmont 2015 ABSTRACT BACKGROUND: Type II diabetes mellitus (T2DM) is a serious and relevant public health problem. Lifestyle programs like the Diabetes Prevention Program (DPP) can delay a patient’s progression to T2DM. Identifying which patients are likely to enroll in these programs and tailoring recruitment approaches to those with perceived barriers is one way to increase engagement in health promotion. Previous literature on antidepressant use and T2DM has raised concerns that antidepressant use is associated with T2DM, however these studies have been variable in quality. Similarly, while statins are one of the most widely prescribed medications in the United States; concern has been raised that they are associated with incident T2DM. The effect of statin use on glycemic control in nondiabetic patients is currently unclear. METHODS: Three retrospective cohort studies were conducted among individuals in the Midwest enrolled in an insurance plan from 2011 through 2014. These studies combined data from medical and pharmacy claims, annual biometric screenings and a health survey. The goal of the first study was to identify differences between prediabetic patients who did and did not volunteer to enroll in a worksite DPP.
    [Show full text]
  • Clearing up Myths About Statins Medication
    Clearing up Myths about Statin Medicine I’ve never been told I have high cholesterol, why do I need a statin? Sometimes people who have a blocked artery or have a health event like a stroke or heart attack may be started on a statin. This is because your risk is now higher to have another stroke or heart attack, even though your cholesterol may be normal. The goal is to lower your risk. Does changing my diet work as well as taking a statin? A heart healthy diet is very important and a great way to prevent a heart attack and stroke. However, statins will lower your risk and your cholesterol more than just changing your diet. As well, statins affect your body in other ways. Statins protect the plaque in your blood vessels from breaking open and causing a heart attack or stroke. What kind of side effects do statins have? Most side effects are mild (such as stomach upset) and go away over time. Less than 10 out of every 100 people who take a statin have side effects. Is it true that statins cause serious muscle problems? A rare side effect of statins is aching muscles. It usually affects large muscles (such as the arms or legs) on both sides of the body. Less than 10 out of every 100 people who take a statin have this side effect. It can usually be managed by lowering the dose or changing to another brand of statin. It doesn’t cause any long-term muscle damage. Rarely, muscle pain may be a sign of a serious muscle problem (about 1 out of every 10,000 people).
    [Show full text]
  • ATC) Classification and the Defined Daily Dose (DDD
    Anatomical Therapeutic Chemical (ATC) classification T and the Defined Daily Dose AF DR (DDD): principles for classifying and quantifying drug use Yong Chen Merck, Whitehouse Station, NJ USA Disclosure • Author is an employee of Merck • A lot of slides are adopted from a prior ICPE English short course on drug utilization by Hege Salvesen Blix 2 Outline • The ATC/DDD methodology – definitions, purpose, structure and principles • Real world applications of ATC/DDD 3 What is ATC/DDD? • ATC (Anatomical Therapeutic Chemical) classification –Don’t confuse it with Anatomical Therapeutic (AT) classification developed by European Pharmaceutical Market Research Association (EPhMRA) • DDD (Defined Daily Dose) The assumed average maintenance dose per day for a drug used for its main indication in adults Introduction to Drug Utilization Research, WHO 2003 4 Main Purpose • “International language for drug utilization research” –to serve as a tool for presenting drug utilization research in order to improve quality of drug use –to compare data within a country and between countries 5 The WHO Collaborating Centre for Drug Statistics Methodology • Established in 1982 as a European WHO Centre • Since 1996 a global WHO Centre • Located in the Department of Pharmacoepidemiology at the Norwegian Institute of Public Health • The staff of the Centre is responsible for drug consumption statistics in Norway 6 The WHO Centre • To classify drugs according to the ATC system and assign DDDs • To review and revise as necessary the ATC classification system and DDDs • To stimulate and influence the practical use of the ATC system • To organize training courses in the ATC/DDD methodology 7 ATC Main Group • A Alimentary tract and metabolism • B Blood and blood forming organs • C Cardiovascular system • D Dermatologicals • G Genito urinary system and sex hormones • H Systemic hormonal preparations, excl.
    [Show full text]
  • How Do Statins Prevent Heart Attacks and Strokes?
    Millions of people in the US take statin medication. The main way statins can reduce your risk of a heart attack or stroke is by lowering your cholesterol levels. Cholesterol is a fatty substance made by the liver. There are two major types of cholesterol: good, HDL, and bad, LDL. Bad cholesterol can leave fatty deposits in your arteries that build up, restricting blood flow and increasing your risk for a heart attack or stroke. If you are already at high risk for a heart attack or stroke, your health care provider may suggest adding a statin in addition to making healthy lifestyle changes. Statins help cut the amount of bad cholesterol your body makes. You'll have a blood test before starting your statin and afterwards, to check if it's lowering your cholesterol. Statins can reduce the amount of fatty deposits in your arteries and stop any more from building up. Statins also make existing deposits less likely to break off and cause a blood clot. A blood clot can cause a heart attack or stroke. It's important to take your statin medication every day. You can remember to take your statin by making it part of your daily routine, like brushing your teeth or eating a meal. Most people don't have side effects from statins, but as with any drug, some people do. Side effects are usually mild. Muscle pain is a possible, though uncommon, side effect. Don’t stop taking your statin if you think you’re having side effects. Your cholesterol level is likely to go up and this could put you at risk for a heart attack or stroke.
    [Show full text]
  • Statin Treatment and the Risk of Depression
    bioRxiv preprint doi: https://doi.org/10.1101/349332; this version posted June 17, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract: 250 words Main text: 3,440 words Figures: 3 Tables: 2 Supplementary material: 2 Tables Statin treatment and the risk of depression Ole Köhler-Forsberg MD1,2, Christiane Gasse PhD2,3,4, Liselotte Petersen PhD2,3,4, Andrew A. Nierenberg MD5,6, Ole Mors MD PhD1,2, Søren Dinesen Østergaard MD PhD2,7,8 1 Psychosis Research Unit, Aarhus University Hospital - Risskov, Risskov, Denmark 2 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark 3 National Centre for Register-based Research, Aarhus University, Aarhus, Denmark 4 Centre for Integrated Register-based Research at Aarhus University (CIRRAU), Aarhus, Denmark 5 Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA 6 Harvard Medical School, Boston, MA, USA 7 Aarhus Institute of Advanced Studies, Aarhus University, Aarhus, Denmark 8 Department of Affective Disorders, Aarhus University, Aarhus, Denmark Corresponding author: Ole Köhler-Forsberg, MD Psychosis Research Unit Aarhus University Hospital - Risskov Skovagervej 2 DK-8240 Risskov Mail: [email protected] Phone: +45 2342 0661 Fax: +45 7847 1609 1 bioRxiv preprint doi: https://doi.org/10.1101/349332; this version posted June 17, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT The effect of statin treatment on the risk of developing depression remains unclear.
    [Show full text]
  • Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
    Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents* Cardiac Drug(s) Enzyme/ Chemotherapy Effect of Drug- Suggested Oncologist Suggested Cardiologist Action Drug† Drug Management Management Interaction Beta-Blockers All beta- Additive Ceritinib Additive Avoid using the combination of ceritinib with beta- blockers clinical bradycardia blockers. If concomitant use is necessary and symptomatic effect bradycardia occurs, hold ceritinib, adjust or discontinue the beta-blocker, and upon recovery resume ceritinib at a reduced dose with frequent monitoring of heart rate.‡ Crizotinib Monitor blood pressure and heart rate regularly. Dose reduction or discontinuation of one of the agents may be necessary if clinically significant bradycardia occurs.‡ Carvedilol P-gp Afatinib ↑ Monitor for adverse Consider alternative agent if inhibition chemotherapy effects of afatinib. If possible. (moderate) drug not well-tolerated, concentration decrease afatinib daily dose by 10 mg. Doxorubicin Monitor for adverse Consider alternative agent if Nilotinib effects of possible. If carvedilol is used for Paclitaxel chemotherapy drug if prevention of anthracycline Pazopanib concomitant therapy is cardiotoxicity, individual risk vs. Vincristine necessary. benefit must be considered. If Vinblastine concomitant therapy is necessary and drug-drug interaction involves QT- prolonging chemotherapy drug, ensure appropriate electrocardiographic (ECG) and electrolyte monitoring. Carvedilol; CYP2D6 Imatinib ↑ beta-blocker Monitor blood pressure
    [Show full text]